PMI
13.6.2019 12:39:03 CEST | Business Wire | Press release
Philip Morris International (PMI) today launches unsmokeyourworld.com , a new online hub for those that want to un smoke themselves or their loved ones, their communities, or the world. The website aims to provide an inspiring and engaging place to help people kick-start their smoke-free journeys. The best way to un smoke is to quit cigarettes and nicotine completely. For adult smokers that don’t the next best option is to switch to a better alternative.
A new survey conducted by Povaddo, commissioned by PMI, shows the potential to improve personal and social relationships by quitting cigarettes. Almost three-quarters—71 percent—of nonsmokers who are in a relationship with a smoking partner said they have had disagreements with their partner because he/she smokes cigarettes. The results showed even higher levels of disagreement in Israel, Italy and Russia, with 80 percent or more stating they have argued with their partner over smoking.
| Have you ever had a disagreement or argument with your partner or spouse because he/she smokes cigarettes? | |||||||||||||
|
Yes |
Russia | U.K. | U.S. | Hong Kong | Israel | Italy | |||||||
| 82% | 63% | 63% | 67% | 80% | 87% | ||||||||
| Japan | Mexico | Australia | Brazil | Denmark | Germany | ||||||||
| 55% | 77% | 68% | 72% | 56% | 55% | ||||||||
| Base: former and never smokers with a partner that smokes | |||||||||||||
Smokers, however, were less likely to recognize the impact that smoking has on their relationships with loved ones, with just, on average, 36 percent of them acknowledging that smoking has caused arguments with their loved ones.
| My smoking causes arguments with loved ones: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Strongly/ Somewhat agree | Russia | U.K. | U.S. | Hong Kong | Israel | Italy | |||||||||||||||||||||||||||||||||||||||||||||||||
| 38% | 32% | 32% | 42% | 43% | 43% | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Japan | Mexico | Australia | Brazil | Denmark | Germany | ||||||||||||||||||||||||||||||||||||||||||||||||||
| 22% | 43% | 25% | 62% | 8% | 22% | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
Base: current and occasional smokers.
Figures have been summed due to rounding |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
“This research shows the scale of the task ahead to help smokers understand the positive impact that unsmoking could have on their relationships,” said Jacek Olczak, Chief Operating Officer, PMI. “We believe that this type of insight should be made known to smokers so they can engage in a conversation and understand the benefits of getting behind the #unsmoke movement.”
Aiming to unify communities toward a smoke-free world, PMI’s unsmokeyourworld.com is an online hub where adult smokers and those that care about them can discover more about ways to un smoke. The site shares stories of un smoke heroes describing their smoke-free journeys and encourages readers to share their own stories.
Olczak continues: “Change comes from communities uniting behind a positive conversation, which is why we have created this place for people to come together and hear each other’s stories for inspiration. This is an important new tool for adult smokers and those who care about them so they can access resources to inspire them to leave cigarettes behind.”
Interactive elements engage readers to understand the facts behind unsmoking and allows them to publicly get involved. Users can add an ‘Un smoke Your World’ overlay to any image they want so they can show support on social media. They can also download and share a selection of gifs to celebrate un smoke successes.
Since April 2019, over 115,000 digital #unsmokeyourworld actions have taken place across the globe—ranging from individuals supporting the campaign on social media to engaging with digital content. PMI’s is calling for people to take action and create a strong movement to an un smoked world. For more information visit, unsmokeyourworld.com .
About the Povaddo Survey
This survey was carried out 24
April-6 May, 2019, by Povaddo, a leading public opinion research firm,
on behalf of Philip Morris International. The survey fielded a total of
16,099 online interviews among general population adults 21-74 years of
age across 13 countries (Argentina, Australia, Brazil, Denmark, Germany,
Hong Kong, Israel, Italy, Japan, Mexico, Russia, United Kingdom and
United States). The survey carries an overall margin of error of +/- 1%
at the 95 percent confidence interval.
About #Unsmokeyourworld
PMI is transforming its business and
increasing awareness of the urgent need to become smoke-free as well as
awareness of better alternatives for smokers who would otherwise
continue to smoke. PMI is producing smoke-free products that are a
better choice for smokers than continued cigarette smoking and can
benefit public health.
#Unsmoke is a PMI initiative to speed up an historic change in public health. Through the #unsmoke movement, we want to bring together a community of people who can accelerate this change by becoming advocates of the message that for smokers who would otherwise continue to smoke, there are better alternatives to choose from.
#Unsmokeyourworld is a global conversation that inspires human stories—for the people, by the people.
About Philip Morris International
Delivering a Smoke-Free
Future Philip Morris International (PMI) is leading a transformation in
the tobacco industry to create a smoke-free future and ultimately
replace cigarettes with smoke-free products to the benefit of adults who
would otherwise continue to smoke, society, the company and its
shareholders. PMI is a leading international tobacco company engaged in
the manufacture and sale of cigarettes, smoke-free products and
associated electronic devices and accessories, and other
nicotine-containing products in markets outside the U.S. PMI is building
a future on a new category of smoke-free products that, while not
risk-free, are a much better choice than continuing to smoke. Through
multidisciplinary capabilities in product development, state-of-the-art
facilities and scientific substantiation, PMI aims to ensure that its
smoke-free products meet adult consumer preferences and rigorous
regulatory requirements. For more information, please visit http://www.pmi.com
and www.pmiscience.com
.
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20190613005304/en/
Contact:
David Fraser Philip Morris International Media Office T. +41 (0)58 242 4500 E. david.fraser@pmi.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
